Fuller & Thaler Asset Management Inc. Boosts Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Fuller & Thaler Asset Management Inc. increased its stake in Amphastar Pharmaceuticals by 11.5% during the first quarter, holding approximately $36.6 million worth of shares.
• Amphastar Pharmaceuticals has received mixed ratings from analysts, with Needham raising it to a "buy" and JPMorgan cutting its price target significantly from $45 to $30.
• The company currently has a market cap of $1.41 billion, with its stock showing a 1-year range from a low of $20.39 to a high of $53.96.

Fuller & Thaler Asset Management Inc. lifted its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 11.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,263,598 shares of the company's stock after purchasing an additional 130,672 shares during the period. Fuller & Thaler Asset Management Inc. owned about 2.66% of Amphastar Pharmaceuticals worth $36,632,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of AMPH. Signaturefd LLC increased its stake in shares of Amphastar Pharmaceuticals by 147.7% in the 1st quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after purchasing an additional 520 shares in the last quarter. IFP Advisors Inc acquired a new stake in Amphastar Pharmaceuticals in the 1st quarter worth about $34,000. GF Fund Management CO. LTD. acquired a new stake in Amphastar Pharmaceuticals in the 4th quarter worth about $38,000. GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 46.6% in the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after buying an additional 424 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Amphastar Pharmaceuticals by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after buying an additional 348 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Trading Down 2.0%

AMPH traded down $0.6250 during trading hours on Monday, reaching $29.8750. The company's stock had a trading volume of 71,402 shares, compared to its average volume of 575,056. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $20.39 and a fifty-two week high of $53.96. The stock has a market cap of $1.39 billion, a PE ratio of 11.22 and a beta of 0.76. The business's 50-day moving average is $24.10 and its 200-day moving average is $25.77. The company has a debt-to-equity ratio of 0.80, a current ratio of 3.29 and a quick ratio of 2.21.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMPH shares. Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Piper Sandler lowered their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating on the stock in a research note on Friday, August 8th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target on the stock in a research note on Tuesday, August 12th. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $31.50.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.